证券代码：832982 证券简称：锦波生物 公告编号：2025-091 山西锦波生物医药股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 7 月 14 日 2.会议召开地点：山西综改示范区太原唐槐园区锦波街 18 号公司九楼会议 室 3.会议召开方式：现场投票及网络投票 4.会议召集人：公司董事会 5.会议主持人：董事长杨霞女士 6.召开情况合法合规的说明： 本次股东会的召集、召开程序符合有关法律、行政法规、部门规章、规范性 文件和本公司章程的相关规定。本次会议召开不需要相关部门的批准或履行其他 必要的程序。 （二）会议出席情况 出席和授权出席本次股东会的股东共 42 人，持有表决权的股份总数 81,182,513 股，占公司有表决权股份总数的 70.55%。 其中通过网络投票参与本次股东会的股东共 20 人，持有表决权的股份总数 4,010,562 股，占公司有表决权股份总数的 ...

Core Insights - The strategic cooperation between Jinbo Bio and Yangshengtang involves a stock issuance and share transfer agreement totaling 3.403 billion yuan [1][2] - If the transaction is completed, Zhong Shanshan, the founder of Nongfu Spring, will become the indirect second-largest shareholder of Jinbo Bio [2] - Jinbo Bio aims to leverage Yangshengtang's strengths in consumer channels, production capacity, and brand recognition to enhance its market presence and product development [2] Company Developments - Jinbo Bio's revenue exceeded 100 million yuan, with net profits ranging between 30 million to 40 million yuan during its listing on the Beijing Stock Exchange [2] - The company views the Beijing Stock Exchange as the most suitable trading venue for its development, benefiting from flexible financing options and enhanced market image [3] Industry Context - The collaboration highlights the growing trend of synergies between biotechnology firms and consumer health companies, aiming to capitalize on each other's strengths in market channels and production capabilities [2]

Industry Overview - The medical beauty injection materials industry in China has a limited number of publicly listed companies, primarily including Huaxi Biological, Haohai Biological, Aimeike, and Juzhi Biological, with most companies involved in the supply of upstream raw materials [1][7]. Company Summaries - Huaxi Biological is a global leader in hyaluronic acid, with a projected revenue of 53.71 billion yuan in 2024, and has expanded into collagen products through acquisitions [2][9]. - Haohai Biological has secured exclusive rights for domestic and international botulinum toxin products and is focusing on a dual product line of hyaluronic acid and botulinum toxin [6][15]. - Aimeike is expected to generate approximately 29.60 billion yuan in sales for its medical beauty injection materials in 2024, emphasizing high-end products [9][15]. - Juzhi Biological is projected to achieve sales of around 55.20 billion yuan in 2024, focusing on collagen products and leading the industry in standard-setting [9][15]. Sales and Production Data - Huaxi Biological has sold over 10 million units of its products, while Haohai Biological and Aimeike have sales around 7 million units each [13]. - Juzhi Biological's collagen products have a sales volume of approximately 55.20 billion yuan, indicating a strong market presence [11][13]. Business Strategies - Huaxi Biological is focusing on core technologies in glyco-biology and cell biology, aiming to enhance its position in the extracellular matrix and anti-aging sectors [15]. - Haohai Biological is pursuing international collaborations and technology imports to strengthen its product offerings and market competitiveness [15]. - Aimeike is developing a high-end product matrix centered on regenerative materials, with significant investments in training and technology [15]. - Juzhi Biological is leading the development of industry standards and expanding its product offerings in the collagen segment [15]. Regional Distribution - The majority of medical beauty injection material companies are concentrated in Shandong Province, with key players in raw material production and equipment manufacturing [7].

Summary of Key Points Core Viewpoint The trading activity on the Beijing Stock Exchange (BSE) showed a decrease in transaction volume and value compared to the previous trading day, with a notable number of stocks experiencing price increases. Trading Volume and Value - On July 10, the total trading volume on the BSE reached 1.064 billion shares, with a total transaction value of 21.134 billion yuan, reflecting a decrease of 1.321 billion yuan from the previous trading day [1]. - Among the traded stocks, 158 stocks closed higher, accounting for 59.40% of the total [1]. Stock Performance - The stocks that hit the daily limit up included Guoyi Bidding and Guangzi International, while the top gainers were Zhongshe Consulting, Jiuling Technology, and Kaida Catalysis, with increases of 13.16%, 9.67%, and 9.09% respectively [1]. - Conversely, 104 stocks closed lower, with the largest declines seen in Jinbo Biology, Shengnan Technology, and Wanda Bearings, which fell by 3.58%, 3.20%, and 2.99% respectively [1]. Active Stocks - A total of 64 stocks had transaction values exceeding 10 million yuan, with the highest transaction values recorded for Ainengju, Jiuling Technology, and Guoyi Bidding at 537.48 million yuan, 517.52 million yuan, and 438.50 million yuan respectively [1]. - The trading activity was characterized by 27 stocks having a turnover rate exceeding 10%, with 7 stocks exceeding 20% [1]. Notable Stocks - The top stocks by turnover rate included Zhongshe Consulting (44.00%), Huawi Design (31.54%), and Ainengju (28.31%) [1]. - The detailed performance of selected stocks is as follows: - Ainengju: Closing price 22.77 yuan, increase 4.45%, turnover rate 28.31%, transaction value 537.48 million yuan [1]. - Jiuling Technology: Closing price 72.60 yuan, increase 9.67%, turnover rate 20.05%, transaction value 517.52 million yuan [1]. - Guoyi Bidding: Closing price 19.11 yuan, increase 30.00%, turnover rate 16.63%, transaction value 438.50 million yuan [1].

截至7月9日，北交所融资融券余额合计59.20亿元，较前一交易日增加38.59万元，其中，融资余额59.19 亿元，较前一交易日增加48.84万元，为连续3个交易日增加；融券余额为104.95万元，较前一交易日减 少10.24万元。 证券时报·数据宝统计显示，截至7月9日，北交所股票中，融资余额居前的为锦波生物、艾融软件、贝 特瑞，最新融资余额分别为3.98亿元、1.71亿元、1.54亿元，从最新融资余额占流通市值比例看，算术 平均值为1.16%，最新融资余额占流通市值比例居前的有天罡股份、胜业电气、巨能股份等，占比分别 为5.50%、4.00%、3.46%。 北交所股票中，7月9日共有123只股获融资净买入，净买入金额在百万元以上的有33只，锦波生物融资 净买入额居首，当日净买入1252.03万元，其次是五新隧装、星图测控，融资净买入金额分别为1150.74 万元、735.85万元，融资净买入金额居前的还有星昊医药、天马新材、奔朗新材等。融资净卖出金额居 前的股票为鼎智科技、远航精密、华岭股份等，融资净卖出金额分别为810.08万元、739.62万元、 426.23万元。 831689 克莱特 -4.40 ...

Group 1 - The A-share pharmaceutical sector has collectively rebounded, with concepts such as recombinant proteins, CRO, biopharmaceuticals, and innovative drugs showing reduced declines [1] - Jinbo Bio has seen an increase of over 3%, with stocks like Shanghai Laishi, Wantai Bio, and Bid Pharma also experiencing gains [1] - Trump previously announced that drug tariffs could reach as high as 200% [1]

以最新收盘价计算，A股平均股价为11.97元，其中股价超过100元的有91只。 百元股作为判定市场热度的信号之一，历来受到投资者关注。证券时报·数据宝统计显示，截至7月8日 收盘，沪指报收3497.48点，上涨0.70%，A股平均股价为11.97元，个股股价分布看，股价超过100元的 有91只，股价在50元至100元的有314只，股价在30元至50元的有732只。 | 688235 | 百济神州 | 223.15 | -0.09 | 0.02 | 医药生物 | | --- | --- | --- | --- | --- | --- | | 688692 | 达梦数据 | 218.80 | 2.72 | 0.01 | 计算机 | | 300760 | 迈瑞医疗 | 217.33 | 0.43 | 0.44 | 医药生物 | | 300779 | 惠城环保 | 210.95 | 3.22 | 4.21 | 环保 | | 688498 | 源杰科技 | 205.90 | 8.33 | 0.07 | 电子 | | 600436 | 片仔癀 | 198.66 | 0.72 | 0.25 | 医药生物 | | 68801 ...

Core Viewpoint - Jinbo Biological is not merely a cosmetic enterprise but a pioneer in the field of human-derived collagen, with significant technological advancements and market potential in the medical sector [1][12]. Group 1: Company Overview - Jinbo Biological (832982.BJ) announced a deep collaboration with Zhong Shanshan's Yangshengtang, involving a total investment of up to 34 billion yuan, which includes a 20 billion yuan capital increase and a 14.03 billion yuan share transfer [2][3]. - The company holds a 100% market share in the category of three types of medical devices related to collagen [2]. - The founder, Yang Xia, has transformed Jinbo Biological into a leader in the recombinant human collagen market, overcoming significant technical challenges [3][11]. Group 2: Technological Advancements - The company successfully developed the first recombinant type III collagen product in 2014, after years of research and overcoming various technical hurdles [5][6]. - In 2018, Jinbo Biological achieved a breakthrough by synthesizing a unique A-type recombinant type III human collagen with a specific triple helix structure, marking a significant advancement in the field [7][8]. - The company received regulatory approval for its recombinant type III human-derived collagen freeze-dried fiber product in June 2021, establishing it as a leader in the new biological materials sector [8][9]. Group 3: Financial Performance - Jinbo Biological's revenue surged from 233 million yuan in 2021 to 780 million yuan in 2023, reflecting a compound annual growth rate of 82.8% [9][12]. - Net profit increased dramatically from 57.39 million yuan to 732 million yuan, with a cumulative growth exceeding 500% [9]. - The gross margin improved from 82.29% in 2021 to 92.02% in 2023, surpassing that of major competitors [9]. Group 4: Market Position and Future Outlook - The company is positioned to enter the international beauty supply chain, including partnerships with major brands like L'Oréal, enhancing its market reach [9][10]. - Jinbo Biological aims to expand its product line to cover various medical applications, including oral, orthopedic, and gynecological fields, focusing on human tissue repair solutions [11][12]. - The market for recombinant collagen in China is projected to reach 58.6 billion yuan by 2025 and exceed 200 billion yuan by 2030, indicating a significant growth opportunity despite increasing competition [12].

2024年，锦波生物公司毛利率为92.02%，同比上升1.86个百分点；净利率为50.68%，较上年同期上升12.39个百分 点。 瑞财经 钟鸣辰近日，锦波生物(BJ832982)发布2024年年度报告，同比净利大增144.27%。 | | | | | 里区: 无 | | --- | --- | --- | --- | --- | | | 2024年 | 2023 年 | 本年比上年 | 2022年 | | | | | 增减% | | | 营业收入 | 1, 442, 831, 399. 69 | 780, 260, 212. 25 | 84. 92% | 390, 198, 402, 96 | | 毛利率% | 92. 02% | 90. 16% | 1 | 85. 44% | | 归属于上市公司股东的净利润 | 732, 301, 620. 38 | 299, 796, 292, 39 | 144. 27% | 109, 175, 008, 63 | | 归属于上市公司股东的扣除非 | 712. 180. 480. 92 | 285, 842, 673. 17 | 149. 15% | 101. 716, ...

Summary of Key Points Market Overview - On July 7, the total trading volume of stocks on the Beijing Stock Exchange reached 864 million shares, with a total transaction value of 18.57 billion yuan, a decrease of 7.596 billion yuan compared to the previous trading day [1] - Among the tradable stocks, 105 stocks closed higher, accounting for 39.47% of the total, with notable gainers including Fangda New Materials, Caneng Power, and Pano Technology, which rose by 9.92%, 8.70%, and 7.80% respectively [1][2] - Conversely, 158 stocks closed lower, with the largest declines seen in Knight Dairy, Baijia Technology, and Qifeng Precision, which fell by 12.73%, 6.19%, and 5.59% respectively [1][2] Trading Activity - A total of 52 stocks had transaction values exceeding 10 million yuan, with the highest transaction values recorded for Guangxin Technology, Tonghui Information, and Caneng Power, at 506 million yuan, 476 million yuan, and 387 million yuan respectively [1] - In terms of trading activity, 26 stocks had a turnover rate exceeding 10%, with 7 stocks exceeding 20%. Additionally, 43 stocks had turnover rates between 5% and 10%, while 180 stocks had turnover rates between 1% and 5% [1] Notable Stocks - The stocks with the highest turnover rates included Caneng Power at 33.99%, Zhongke Meiling at 33.72%, and Tonghui Information at 31.46% [1] - The closing prices and performance of selected stocks are as follows: - Guangxin Technology: 75.97 yuan, up 2.11%, turnover rate 22.24%, transaction value 505.65 million yuan - Tonghui Information: 11.25 yuan, up 2.74%, turnover rate 31.46%, transaction value 475.69 million yuan - Caneng Power: 24.86 yuan, up 8.70%, turnover rate 33.99%, transaction value 386.55 million yuan [1][2]